Pulling SEC filings + quote and writing the call…

TRUPANION, INC.
Next earnings Aug 5, 2026 (after close) · consensus $0.11 EPS, $398M rev
Last earnings -4.3% on 2026-04-30
Inflection to profitability is real but fragile — subscription pets grow while total pets shrink, and PAC is climbing fast.
Revenue $1.44B · FY2025
Middling fundamentals and a rich price (~88% above fair value) leave little margin of safety — a wait-and-see.
Trupanion has crossed a long-awaited inflection: FY2025 delivered $1.44B revenue (+11.9% YoY), operating income of $13.8M (+245% YoY), $0.45 diluted EPS, and $89.5M of operating cash flow (+85% YoY). The MD&A confirms the underlying mix is improving — subscription pets grew from 1,041,212 to 1,096,173 and monthly ARPU climbed from $72.98 to $80.79 (and to $83.56 in Q4), so the core subscription engine is pricing through veterinary inflation while keeping retention near 98.3%. Long-term debt was paid down 20% to $102M and equity grew 19% to $384M, so the balance sheet is healthier than at any point in the company's history of cumulative losses (accumulated deficit still -$206M per the 10-K).
The filing language, however, undercuts an outright buy. Total pets enrolled actually fell from 1,677,570 to 1,647,565 — the headline growth is entirely mix-driven (higher ARPU on a smaller pet base), as Pets Best run-off in the 'other business' segment masks the subscription gains. Average pet acquisition cost has exploded from $235 to $288 for the year, and $320 in Q4 versus $261 a year prior — a 23% jump that management explicitly flags as a key efficiency metric. The Risk Factors single out 'variable costs of attracting new members through online channels' and the need to 'maintain certain levels of surplus capital' under insurance regs, plus the planned roll-off of the Accelerant fronting relationship in Canada (GPIC will underwrite directly) — a non-trivial operational transition.
Is TRUP a buy? The one-page verdict, explained →
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $699M | $905M | $1.11B | $1.29B | $1.44B |
| Gross profit | — | — | — | — | — |
| Operating income | -$35.2M | -$43.0M | -$40.7M | -$9.51M | $13.8M |
| Net income | — | — | — | — | — |
| Diluted EPS | -$0.89 | -$1.10 | -$1.08 | -$0.23 | $0.45 |
| Net margin | — | — | — | — | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results (Item 5.07); routine governance disclosure.
Q1 2026 results; continued ARPU growth and margin expansion off 2025 turnaround.
Q1 2026 results; continued ARPU growth and margin expansion off 2025 turnaround.
Proxy: routine board, comp and auditor ratification ahead of annual meeting.
Proxy: routine board, comp and auditor ratification ahead of annual meeting.
FY25: first profitable year, op income $13.8M, OCF $89.5M, ARPU $80.79 (+11%).
Q4/FY2025 earnings release: revenue $1.44B (+12%), op income +245%, EPS $0.45.
Q3'25: ARPU $82, sub pets +5% YoY; PAC rising to $290 pressures acquisition ROI.
Q3'25: ARPU $82, sub pets +5% YoY; PAC rising to $290 pressures acquisition ROI.
Sources: SEC EDGAR (CIK 0001371285, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 6/25/2026, 2:18:12 PM.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 10:18 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 4 sales
| 2026-06-29 | GALLAGHER JOHN R Chief Operating Officer | Sell | 431.00 @ $25.35 | $10.9K |
| 2026-06-05 | WEINRAUCH STEVE EVP, North Am & Vet Strategy | Exercise | 8.50K @ $15.46 | $131K |
| 2026-06-05 | WEINRAUCH STEVE EVP, North Am & Vet Strategy | Sell | 6.67K @ $22.00 | $147K |
| 2026-05-28 | GALLAGHER JOHN R Chief Operating Officer | Sell | 3.60K @ $21.69 | $78.2K |
| 2026-05-25 | WHEELER SIMON EVP, Trupanion International | Exercise | 321.00 | |
| 2026-05-25 | WHEELER SIMON EVP, Trupanion International | Tax | 150.00 @ $21.86 | $3.28K |
| 2026-05-25 | Tooth Margaret CEO | Exercise | 1.25K | |
| 2026-05-25 | Tooth Margaret CEO | Sell | 491.00 @ $21.86 | $10.7K |
| 2026-05-25 | MCGIBNEY BRENNA Chief Administration Officer | Exercise | 234.00 | |
| 2026-05-25 | MCGIBNEY BRENNA Chief Administration Officer | Tax | 125.00 @ $21.86 | $2.73K |
| 2026-05-25 | MCGIBNEY BRENNA Chief Administration Officer | Exercise | 31.00 | |
| 2026-05-25 | MCGIBNEY BRENNA Chief Administration Officer | Tax | 16.00 @ $21.86 | $349.76 |
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.